Clin2
NCT05623501Worth exploringNot yet recruiting

Dihydromyricetin for early alcohol-related liver injury

Alcohol-Related Disorders

Part of Mental health clinical trials.

This early-stage study tests a supplement-like drug called dihydromyricetin to see what dose is safe and whether it can help prevent or improve alcohol-associated liver disease. It is meant for adults who have not yet developed significant liver damage and do not have alcohol use disorder.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
12 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • Be 18 to 60 years old
  • No history of alcohol use disorder or alcohol-associated liver disease
  • Weigh at least 50 kg
  • Do not have advanced liver disease or other acute (sudden) liver problems
  • Not pregnant and willing to avoid pregnancy during the study
  • Have no HIV infection, pancreatic/biliary disease, or other conditions that could block absorption of the study drug
  • Not taking certain medicines that strongly affect a liver enzyme called CYP3A4
  • Your liver blood test risk score (FIB-4) must be 1.30 or less (not above 1.30)
  • On the AUDIT questionnaire, your score must be 8 or less (no alcohol use disorder by this test)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06070649Recruiting· Phase 1
DMT for Alcohol Use Disorder

This trial tests whether a single dose of DMT, a psychedelic, can help people with alcohol use disorder. It's a small early-phase study to see if the treatment is safe and promising.

New Haven, Connecticut
NCT06636227Recruiting· Phase 1
Diclofenac dose study for alcohol use disorder

This study tests whether different doses of diclofenac, an anti-inflammatory drug, can help people reduce heavy drinking. It looks at how the drug affects drinking patterns and overall health.

Catonsville, Maryland
NCT07791043Not yet recruiting· Phase 2
Efimosfermin alfa for alcohol-related liver disease

This study tests an investigational medicine called efimosfermin alfa to see if it is safe and effective for people with liver damage caused by heavy drinking. The medicine is compared to a placebo (a dummy treatment).

NCT06613698Recruiting· Phase 2
Testing an investigational drug for alcohol-related liver disease

This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.

Chandler, Arizona
NCT03503708Not yet recruiting
Herbal supplements for liver function in alcohol-related liver disease

This trial tests whether specific herbal supplements can improve liver health in adults with alcohol-related liver disease. It aims to see if the supplement safely improves liver blood tests and overall liver function.

Bangalore, Karnataka
NCT06493773Recruiting
Alcohol help for new liver disease diagnosis

This trial tests a program to help people recently diagnosed with alcohol-related liver disease cut back on drinking. If you qualify, you may get support to improve your liver health.

Køge, Køge

Hear when a new Alcohol-Related Disorders trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.